To evaluate the efficacy and adverse reactions of Shenyi capsule combined with paclitaxel in the treatment of patients with non-small cell lung cancer (NSCLC).Methods:A hundred patients with NSCLC admitted in in the hospital from January 2010 to March 2013 were included.All patients were divided into observation group and control group according to the intention of patients.Patients in observation group were given Shenyi capsule combined with paclitaxel treatment,and patients in control group were given paclitaxle treatment sorely.The long term survival and adverse reactions were observed and compared between the two groups.At the same time,the level of vascular endothelial growth factor (VEGF) was detected and compared using enzyme-linked immunosorbent method.Results:The total effective rate in observation group was 67.9%,which was higher than that of 47.7% in control group.The difference is statistically significant (P<0.05).The 1 year,2 year survival rates in observation group were 42.9% and 25.0%,which were higher than 22.7% and 9.1% in the control group.The difference is statistically significant (P<0.05).The average survival time in observation group was longer than that of the control group,and the differences was statistically significant (P<0.05).The VEGF levels after treatment in two groups were lower than those before treatment and the difference is statistically significant (P<0.05).The VEGF levels in observation group after treatment were lower than that of the control group,and the difference is statistically significant (P<0.05).Conclusion:Shenyi capsule combined with paclitaxel can prolong the survival time,improve quality of life to patients with NSCLC.Also,it can low the levels of VEGF,which is worthy of clinical promotion.